MedTrace Logo

Investigating the Role of Diazepam on Brain Function and Chemistry in Psychosis Risk

NCT06190483 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-01-05

No results posted yet for this study

Summary

This study will investigate whether a single dose of diazepam (5mg) compared to placebo can modulate brain chemistry (GABA/glutamate levels) and function (blood flow, neural response and connectivity during tasks and at-rest) in 24 individuals at clinical high-risk for psychosis.

Conditions

  • Prodromal Schizophrenia

Interventions

DRUG

Diazepam 5 Mg Oral Tablet

Single dose given orally (opaque capsule) 60 minutes prior to MRI scan

DRUG

Ascorbic Acid 50 Mg Oral Tablet

Single dose given orally (opaque capsule) 60 minutes prior to MRI scan

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • The Royal Society

    collaborator UNKNOWN

  • King's College London

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-24
Primary Completion
2023-03-24
Completion
2023-03-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06190483 on ClinicalTrials.gov